



**Universiteit
Leiden**
The Netherlands

Association of immune-related adverse event management with survival in patients with advanced melanoma

Not, O.J. van; Verheijden, R.J.; Eertwegh, A.J.M. van den; Haanen, J.B.A.G.; Aarts, M.J.B.; Berkmortel, F.W.P.J. van den; ... ; Suijkerbuijk, K.P.M.

Citation

Not, O. J. van, Verheijden, R. J., Eertwegh, A. J. M. van den, Haanen, J. B. A. G., Aarts, M. J. B., Berkmortel, F. W. P. J. van den, ... Suijkerbuijk, K. P. M. (2022). Association of immune-related adverse event management with survival in patients with advanced melanoma. *Jama Oncology*, 8(12), 1794-1801. doi:10.1001/jamaoncol.2022.5041

Version: Publisher's Version

License: [Licensed under Article 25fa Copyright Act/Law \(Amendment Taverne\)](#)

Downloaded from: <https://hdl.handle.net/1887/3564012>

Note: To cite this publication please use the final published version (if applicable).

Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma

Olivier J. van Not, MD; Rik J. Verheijden, BSc; Alfonsus J. M. van den Eertwegh, MD, PhD; John B. A. G. Haanen, MD, PhD; Maureen J. B. Aarts, MD, PhD; Franchette W. P. J. van den Berkmortel, MD, PhD; Christian U. Blank, MD, PhD; Marye J. Boers-Sonderen, MD, PhD; Jan-Willem B. de Groot, MD, PhD; Geke A. P. Hospers, MD, PhD; Anna M. Kamphuis, MD, PhD; Ellen Kapiteijn, MD, PhD; Anne M. May, MD, PhD; Melissa M. de Meza, MD; Djura Piersma, MD, PhD; Rozemarijn van Rijn, MD, PhD; Marion A. Stevense-den Boer, MD, PhD; Astrid A. M. van der Veldt, MD, PhD; Gerard Vreugdenhil, MD, PhD; Willeke A. M. Blokk, MD, PhD; Michel J. M. Wouters, MD, PhD; Karijn P. M. Suijkerbuijk, MD, PhD

IMPORTANCE Management of checkpoint inhibitor-induced immune-related adverse events (irAEs) is primarily based on expert opinion. Recent studies have suggested detrimental effects of anti-tumor necrosis factor on checkpoint-inhibitor efficacy.

OBJECTIVE To determine the association of toxic effect management with progression-free survival (PFS), overall survival (OS), and melanoma-specific survival (MSS) in patients with advanced melanoma treated with first-line ipilimumab-nivolumab combination therapy.

DESIGN, SETTING, AND PARTICIPANTS This population-based, multicenter cohort study included patients with advanced melanoma experiencing grade 3 and higher irAEs after treatment with first-line ipilimumab and nivolumab between 2015 and 2021. Data were collected from the Dutch Melanoma Treatment Registry. Median follow-up was 23.6 months.

MAIN OUTCOMES AND MEASURES The PFS, OS, and MSS were analyzed according to toxic effect management regimen. Cox proportional hazard regression was used to assess factors associated with PFS and OS.

RESULTS Of 771 patients treated with ipilimumab and nivolumab, 350 patients (median [IQR] age, 60.0 [51.0-68.0] years; 206 [58.9%] male) were treated with immunosuppression for severe irAEs. Of these patients, 235 received steroids alone, and 115 received steroids with second-line immunosuppressants. Colitis and hepatitis were the most frequently reported types of toxic effects. Except for type of toxic effect, no statistically significant differences existed at baseline. Median PFS was statistically significantly longer for patients treated with steroids alone compared with patients treated with steroids plus second-line immunosuppressants (11.3 [95% CI, 9.6-19.6] months vs 5.4 [95% CI, 4.5-12.4] months; $P = .01$). Median OS was also statistically significantly longer for the group receiving steroids alone compared with those receiving steroids plus second-line immunosuppressants (46.1 months [95% CI, 39.0 months-not reached (NR)] vs 22.5 months [95% CI, 36.5 months-NR]; $P = .04$). Median MSS was also better in the group receiving steroids alone compared with the group receiving steroids plus second-line immunosuppressants (NR [95% CI, 46.1 months-NR] vs 28.8 months [95% CI, 20.5 months-NR]; $P = .006$). After adjustment for potential confounders, patients treated with steroids plus second-line immunosuppressants showed a trend toward a higher risk of progression (adjusted hazard ratio, 1.40 [95% CI, 1.00-1.97]; $P = .05$) and had a higher risk of death (adjusted hazard ratio, 1.54 [95% CI, 1.03-2.30]; $P = .04$) compared with those receiving steroids alone.

CONCLUSIONS AND RELEVANCE In this cohort study, second-line immunosuppression for irAEs was associated with impaired PFS, OS, and MSS in patients with advanced melanoma treated with first-line ipilimumab and nivolumab. These findings stress the importance of assessing the effects of differential irAE management strategies, not only in patients with melanoma but also other tumor types.

JAMA Oncol. 2022;8(12):1794-1801. doi:10.1001/jamaoncol.2022.5041
Published online October 27, 2022.

 Multimedia

 Supplemental content

Author Affiliations: Author affiliations are listed at the end of this article.

Corresponding Author: Olivier J. van Not, MD, Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Postbus 85500, 3508 GA Utrecht, the Netherlands (o.j.vannot@umcutrecht.nl).

The introduction of immune checkpoint inhibitors (ICIs) has greatly improved the prognosis of patients diagnosed with advanced melanoma.^{1,2} However, blocking immunological checkpoints, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or programmed cell death 1 (PD-1), may lead to immune-related adverse events (irAEs). In the phase 3 CheckMate 067 trial,³ 96% of patients experienced any irAE, and 59% experienced grade 3 or higher irAEs when treated with a combination of CTLA-4 and PD-1 antibodies.

Because irAEs result from immune activation, the occurrence of irAEs has been hypothesized to be associated with improved ICI efficacy. Data on this toxicity-efficacy relationship are inconsistent, prone to immortal time bias, and heterogeneous in cancer type, ICI regimen, and severity of toxic effects. Nevertheless, an increasing body of evidence seems to support this hypothesis.⁴⁻⁹

The management of irAEs is based mainly on expert opinion,¹⁰ and data on the effect of immunosuppressive therapy on ICI efficacy are limited. Although administration of steroids for irAEs has generally been considered safe,^{11,12} a more recent study questions this to be the case for early high-dose steroids.¹³ The effect of tumor necrosis factor (TNF) blockade on the survival of patients with advanced melanoma has been a matter of debate.¹⁴⁻¹⁶ A recent study by our group⁹ showed an association between the use of TNF blockade for irAEs and impaired survival in a mixed population of patients with advanced melanoma treated with ipilimumab, anti-PD-1 therapy, or combination ipilimumab and nivolumab. An important remaining question is if a potentially harmful effect could be attributed to anti-TNF specifically or regarded as the result of escalated and long-term immunosuppression. In this cohort study, we investigated the association among different immunosuppressive regimens for grade 3 and higher irAEs with overall survival (OS) and progression-free survival (PFS) in a more homogeneous cohort of patients with advanced melanoma, all treated with first-line ipilimumab and nivolumab.

Methods

Study Design

For this study, we used data from the Dutch Melanoma Treatment Registry (DMTR). The DMTR has prospectively registered data of all patients with unresectable stage IIIc and IV melanoma in the Netherlands since 2012. The data in the DMTR are registered by independent data managers who are trained annually. To further ensure the data quality, patients' data are checked by their treating physicians.¹⁷

All patients with advanced cutaneous melanoma treated with first-line ipilimumab-nivolumab combination therapy registered in the DMTR between April 2015 and December 2021 were included in this study, with survival analyses focusing on patients who experienced severe irAEs. We stratified patients according to their management of toxic effects: steroids alone vs steroids with any second-line immunosuppressant. For the second analysis, the latter group of patients receiving steroids with any second-line immunosuppressant

Key Points

Question Is there an association among different immunosuppressive treatments for grade 3 and higher immune-related adverse events (irAEs) and progression-free survival or overall survival in patients with advanced melanoma treated with first-line ipilimumab-nivolumab combination therapy?

Findings In this cohort study including 771 patients with advanced melanoma who were treated with ipilimumab and nivolumab, 350 patients were treated with immunosuppression for severe irAEs. Use of second-line immunosuppression, irrespective of the type, was associated with impaired progression-free survival and overall survival.

Meaning These results suggest harmful effects of escalated immunosuppression for irAEs, which warrants further investigation to identify detrimental factors within current irAE management approaches.

was further divided into those receiving steroids with anti-TNF vs those receiving steroids with other second-line immunosuppressants (excluding anti-TNF). Other immunomodulating medications consisted of mycophenolic acid, tacrolimus, and other nonspecified immunosuppressants.

Baseline characteristics, reasons for treatment discontinuation, and survival outcomes were compared between the different groups. For this study, the data set cutoff date was December 14, 2021. Research using DMTR data was approved by the medical ethical committee and was not deemed subject to the Medical Research Involving Human Subjects Act in compliance with Dutch regulations, thus patient informed consent was not required.

Patient Characteristics

The registered patient and tumor characteristics at diagnosis that were used for this analysis included (1) age at diagnosis, (2) sex, (3) Eastern Cooperative Oncology Group Performance Status, (4) lactate dehydrogenase levels, (5) liver metastasis, (6) brain metastasis, (7) stage according to the American Joint Committee on Cancer, 8th edition,¹⁸ and (8) *BRAF*, *NRAS*, and *KIT* variation status. Furthermore, data on the type of toxic effects and treatments used to manage toxic effects were registered.

Response evaluation was determined by the treating physician and was based on the Response Evaluation Criteria in Solid Tumors, version 1.1.¹⁹ Progression-free survival was calculated from the start of systemic therapy until progression or death by any cause. Overall survival was calculated from the start of systemic therapy until death by any cause or last moment of follow-up. Patients not reaching the end point were censored at the date of the last contact. Melanoma-specific survival was calculated from the start of systemic therapy until melanoma-related death. Patients dying of other causes were censored.

Statistical Analysis

Baseline characteristics were analyzed using descriptive statistics. Pearson χ^2 test was used to compare categorical vari-

ables, and the Wilcoxon test was used for continuous variables. Median follow-up time was estimated from the date of the first visit using the reversed Kaplan-Meier method.²⁰ Median PFS and OS were calculated using the Kaplan-Meier method. A Cox proportional hazards model was used to perform a multivariable regression analysis to assess factors associated with PFS and OS. Comparisons were considered statistically significant for 2-sided $P < .05$. Data handling and statistical analyses were performed using Rstudio, version 4.0.2 (R Foundation),²¹ packages survival,²² and survminer.²³

Results

Patient Characteristics

Of 771 patients treated with first-line combination ipilimumab and nivolumab, 385 patients (49.9%) experienced grade 3 or higher irAEs. Eighty-five percent ($n = 327$) of these patients were not included in our previous study.⁹ Of the patients experiencing grade 3 or higher irAEs, 235 received steroids alone, and 115 received steroids plus any second-line immunosuppressant. Patients treated with steroids plus any second-line immunosuppressant more often experienced colitis than patients who received steroids only (80 [69.6%] vs 66 [28.1%]; $P < .001$), which was the opposite for hepatitis (36 [31.3%] vs 103 [43.8%]; $P = .03$), and endocrine-related toxic effects (6 [5.2%] vs 37 [15.7%]; $P = .008$). Colitis ($n = 146$) and hepatitis ($n = 139$) were the most frequently reported toxic effects. There were no other statistically significant differences at baseline between the 2 groups (Table). Of the 115 patients treated for their irAE(s) with any second-line immunosuppressant, 67 received steroids plus anti-TNF and 35 received steroids plus other second-line immunosuppressants excluding anti-TNF.

Patient characteristics of these groups are summarized in eTable 1 in the Supplement. Specification of the irAE management strategy of the group receiving steroids plus other second-line immunosuppressants excluding anti-TNF is summarized in eTable 2 in the Supplement. Thirteen patients were excluded from this last analysis because they received both anti-TNF and other second-line immunosuppressants. Management strategies for these patients are summarized in eTable 3 in the Supplement. Median follow-up was 23.6 months.

Progression-Free Survival

Patients treated with steroids alone had a statistically significant longer median PFS (11.3 [95% CI, 9.6-19.5] months) compared with patients treated with steroids plus any second-line immunosuppressant (5.4 [95% CI, 4.5-12.4] months; hazard ratio [HR], 1.43 [95% CI, 1.07-1.90]; $P = .01$; Figure 1A). In multivariable analysis, there was a strong trend of a higher risk of progression or death for patients receiving any second-line immunosuppressant next to steroids (adjusted HR [aHR], 1.40 [95% CI, 1.00-1.97]; $P = .05$; Figure 2A).

Progression-free survival was statistically significantly longer in the steroids-only group compared with the groups receiving steroids plus anti-TNF (median PFS, 5.4 [95% CI, 4.7-13.1] months; HR, 1.44 [95% CI, 1.02-2.02]; $P = .04$) and steroids

plus other immunosuppressants excluding anti-TNF (median PFS, 4.3 [95% CI, 2.5-13.2] months; HR, 1.65 [95% CI, 1.07-2.56]; $P = .02$). No statistically significant difference in PFS existed between the groups receiving steroids plus anti-TNF and steroids plus other second-line immunosuppressants excluding anti-TNF (HR, 1.17 [95% CI, 0.71-1.92]; $P = .54$; eFigure 1A in the Supplement). Multivariable analysis showed no statistically significantly higher risk of progression or death for patients receiving steroids plus anti-TNF (aHR, 1.44 [95% CI, 0.92-2.26]; $P = .11$) but did show a higher risk of progression or death for patients receiving steroids plus other second-line immunosuppressants excluding anti-TNF compared with steroids only (aHR, 1.62 [95% CI, 1.02-2.57]; $P = .04$; eFigure 2A in the Supplement).

Overall Survival

Patients treated with steroids alone had a statistically significant longer median OS (46.1 months [95% CI, 39.0 months-not reached [NR]] compared with patients receiving steroids plus any second-line immunosuppressant (median OS, 22.5 months [95% CI, 36.5 months-NR]; HR, 1.64 [95% CI, 1.16-2.32]; $P = .005$; Figure 1B). After adjusting for potential confounders, the risk of death remained statistically significantly higher for patients receiving any second-line immunosuppressant next to steroids (aHR, 1.54 [95% CI, 1.03-2.30]; $P = .04$; Figure 2B).

Median OS was also statistically significantly longer for patients receiving steroids alone compared with steroids plus anti-TNF (median OS, 28.7 months [95% CI, 12.2 months-NR]; HR, 1.62 [95% CI, 1.07-2.46]; $P = .02$), but not compared with steroids plus other second-line immunosuppressants excluding anti-TNF (median OS, 22.4 months [95% CI, 13.2 months-NR]; HR, 1.59 [95% CI, 0.95-2.65]; $P = .08$). No statistically significant difference in OS was found between patients receiving steroids plus anti-TNF and steroids plus other second-line immunosuppressants excluding anti-TNF (HR, 0.99 [95% CI, 0.56-1.76]; $P = .97$; eFigure 1B in the Supplement). After adjusting for potential confounders, the differences in risk of death between these subgroups were no longer statistically significant (eFigure 2B in the Supplement). The observed trends in OS were also seen for melanoma-specific survival (eFigures 3 and 4 in the Supplement).

Treatment Duration and Discontinuation

In the group receiving steroids plus any second-line immunosuppression, median (IQR) treatment duration (TD) was 44 (21-102) days. This was not statistically significantly different from patients treated with steroids plus any second-line immunosuppressants (median [IQR] TD, 40 [21-63] days). Patients treated with steroids plus anti-TNF had a median (IQR) TD of 42 (21-63) days, and patients treated with steroids plus other second-line immunosuppressants excluding anti-TNF had a median (IQR) TD of 21 (21-44) days.

Statistically significantly more patients discontinued treatment due to toxic effects in the group receiving steroids plus any second-line immunosuppressants ($n = 102$ [88.7%]) compared with patients receiving steroids only ($n = 171$ [72.8%]) ($P = .02$; eTable 4 in the Supplement). There were

Table. Patient Characteristics Stratified by Management of Toxic Effects in Patients With Advanced Melanoma Treated With First-line Ipilimumab and Nivolumab

Characteristic	Treatment, No. (%)		P value
	Steroids (n = 235)	Steroids + any second-line immunosuppressant (n = 115)	
Age, y			
<70	187 (79.6)	84 (73.0)	.22
≥70	48 (20.4)	31 (27.0)	
Age, median (IQR), y	60.0 (52.0-68.0)	60.0 (50.0-70.0)	.95
Sex			
Female	101 (43.0)	43 (37.4)	.38
Male	134 (57.0)	72 (62.6)	
ECOG PS			
0	129 (54.9)	53 (46.1)	.39
1	82 (34.9)	49 (42.6)	
≥2	14 (6.0)	6 (5.2)	
Liver metastases			
No	157 (66.8)	74 (64.3)	.52
Yes	76 (32.3)	41 (35.7)	
Brain metastases			
No	142 (60.4)	61 (53.0)	.47
Yes (asymptomatic)	61 (26.0)	34 (29.6)	
Yes (symptomatic)	31 (13.2)	20 (17.4)	
Organ sites			
<3	112 (47.7)	47 (40.9)	.37
≥3	122 (51.9)	68 (59.1)	
Unknown	1 (0.4)	0	
AJCC, 8th edition, stage			
IIIc unresectable	12 (5.1)	5 (4.3)	.32
IV-M1a	3 (1.3)	4 (3.5)	
IV-M1b	20 (8.5)	5 (4.3)	
IV-M1c	107 (45.5)	47 (40.9)	
IV-M1d	92 (39.1)	54 (47.0)	
LDH levels			
Normal	119 (50.6)	60 (52.2)	.72
250-500 U/L	80 (34.0)	39 (33.9)	
>500 U/L	31 (13.2)	14 (12.2)	
Gene variation			
<i>BRAF</i>	90 (38.3)	54 (47.0)	.15
<i>NRAS</i>	70 (29.8)	33 (28.7)	.93
<i>KIT</i>	3 (1.3)	1 (0.9)	>.99
Toxic effect type ^a			
Colitis	66 (28.1)	80 (69.6)	<.001
Hepatitis	103 (43.8)	36 (31.3)	.03
CNS toxic effect or neuropathy	15 (6.4)	7 (6.1)	>.99
Nephritis	17 (7.2)	3 (2.6)	.13
Pneumonitis	21 (8.9)	4 (3.5)	.10
Endocrine related	37 (15.7)	6 (5.2)	.008
Dermatitis	32 (13.6)	7 (6.1)	.06
Cardiac toxic effect	2 (0.9)	0 (0.0)	.81
Other ^b	10 (4.3)	2 (1.7)	.37

Abbreviations: AJCC, American Joint Committee on Cancer; CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group Performance Status; LDH, lactate dehydrogenase.

SI conversion factor: To convert LDH to microkatal per liter, multiply by 0.0167.


^a Patients may experience multiple toxic effects.

^b Other consisted of any toxic effects outside the categories mentioned.

no statistically significant differences in reasons for treatment discontinuation among patients receiving steroids alone, steroids with anti-TNF, or steroids with other second-

line immunosuppressants excluding anti-TNF, but this could be a consequence of small patient numbers (eTable 5 in the Supplement).

Figure 1. Survival Stratified by Management of Toxic Effects in Patients With Advanced Melanoma Treated With First-line Ipilimumab and Nivolumab



The dashed lines represent the median survivals.

Discussion

In this nationwide cohort study, we showed that patients with melanoma who received second-line immunosuppressants for toxic effects had a shorter PFS and OS than those whose irAEs were managed with steroids only. While we previously demonstrated the detrimental effects of anti-TNF in this setting,⁹ the current data demonstrate inferior survival for all patients receiving second-line immunosuppressants. Because the size of the subgroups of patients receiving anti-TNF or other immunosuppressants (excluding anti-TNF) were small, the present data are inconclusive on whether this impaired survival is associated with the use of anti-TNF specifically or accelerated immunosuppression in general.

Controversy exists regarding the effect of TNF inhibition as irAE treatment on ICI efficacy. Our previous study showed that patients with melanoma and severe irAEs treated with TNF inhibition had worse OS than patients who only received steroids.⁹ Analyzing 1250 patients with melanoma treated with first-line ICIs, we showed that the 312 patients who experienced severe ICI-related toxic effects had a statistically significantly prolonged survival. The median OS of patients experiencing grade 3 or higher irAEs was 23 months compared with 15 months for patients without severe toxic effects (aHR, 0.77; 95% CI, 0.63-0.93). Among patients with severe toxic effects, median OS was 17 months in patients who were treated with anti-TNF plus steroids compared with 27 months in patients who received steroids only (aHR, 1.61; 95% CI, 1.03-2.51). In contrast with the present current homogeneous cohort, our previous study contained a mix of ICI treatments, with most patients receiving anti-CTLA-4 or anti-PD-1 monotherapy, which raised concerns about residual confounding.²⁴ The homogeneous cohort of patients treated with first-line ipilimumab and nivolumab allowed us to evaluate differences in PFS. Comparing patients with and without irAEs was not the focus of the current study. However, we once more found that patients with severe irAEs treated with steroids only had a statistically significant better PFS and OS than patients not ex-

periencing severe irAEs. This survival benefit was not found for patients whose irAEs were managed with second-line immunosuppressants (eFigure 5 in the Supplement).



Two small retrospective studies did not show a difference in survival or time to treatment failure between patients with advanced cancer and ICI-induced colitis treated with steroids alone or steroids plus TNF inhibition.^{25,26} However, with only 35 and 36 patients treated with anti-TNF, respectively, these studies were underpowered to observe meaningful effects of immunosuppressants on ICI efficacy. Two other small studies have described the effects of anti-TNF for ICI-related colitis in 27 and 19 patients, respectively.^{27,28} Although the authors concluded that compared with historical controls, anti-TNF did not appear to negatively influence survival, their median OS of 9 and 12 months, respectively, compared unfavorably with OS in recent studies.²

Zou and colleagues²⁹ conducted a retrospective comparison in a heterogeneous cohort of patients with cancer who received TNF inhibition (infliximab), vedolizumab (an integrin inhibitor), or both as second-line immunosuppressants for colitis or diarrhea induced by anti-PD-1, anti-CTLA-4, or combined ICIs. They found an inferior response and OS of patients treated with infliximab compared with vedolizumab. As the authors acknowledge, survival and tumor response were not the primary end points of this study.

The present results suggest that escalated immunosuppression for toxic effects compromises ICI efficacy. Although a link with the use of second-line immunosuppressants seems likely, we cannot completely rule out the effects of protracted high-dose steroid treatment in the patients receiving second-line immunosuppressants. Indeed, early high dosage of steroids and prolonged steroid treatment have been correlated with worse survival.^{8,13} Unfortunately, data on steroid dosage and duration have not been registered in the DMTR. Of note, steroid titration was previously shown to commence earlier in patients receiving second-line anti-TNF, with numerically shorter steroid duration.²⁶

More severe irAEs tend to occur earlier.^{30,31} Because ICIs are generally discontinued in case of severe irAEs,^{10,32} a shorter

Figure 2. Cox Proportional Hazard Model of Survival Stratified by Management of Toxic Effects in Patients With Advanced Melanoma Treated With First-line Ipilimumab and Nivolumab



ICI exposure in patients with more severe irAEs could theoretically explain survival differences. However, in this study, no relevant difference in ICI treatment duration existed between patients with and without second-line immunosuppression. In the present cohort, second-line immunosuppression was highly associated with the type of toxic effect. In line with what was previously shown by Bai et al,¹³ we did not find

a survival difference according to the type of irAE. Moreover, adjustment for the type of toxic effect in the multivariable analysis did not change the results.

Limitations

This study has several limitations. First, although we know the types of severe irAEs patients had, it was not registered which

immunosuppressants were given for treatment of which irAE. Second, the lack of data on duration and dosage of immunosuppressants prohibits strong conclusions about a causal link between the use of second-line immunosuppressants and patient outcomes.

Conclusions

In this cohort study, data showed that survival was worse in patients with irAEs treated with escalated immunosuppress-

sion compared with those managed with only steroids. The current results suggest harmful effects of escalated immunosuppression rather than a specific anti-TNF-related effect.

A randomized clinical trial comparing treatment with infliximab vs the gut-specific vedolizumab in patients with ICI-induced colitis is currently being conducted³³ but unfortunately is not powered on ICI-efficacy end points. With up to 40% of patients with advanced cancer currently being eligible for ICIs,³⁴ the relevance of this research reaches beyond the melanoma field and urges more randomized studies, also in other tumor types.

ARTICLE INFORMATION

Accepted for Publication: July 27, 2022.

Published Online: October 27, 2022.

doi:10.1001/jamaoncol.2022.5041

Author Affiliations: Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, the Netherlands (van Not, de Meza, Wouters); Department of Medical Oncology, University Medical Centre Utrecht, Utrecht, the Netherlands (van Not, Verheijden, Kamphuis, Suijkerbuijk); Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands (van den Eertwegh); Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands (Haanen, Blank); Department of Medical Oncology, GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, the Netherlands (Aarts); Department of Medical Oncology, Zuyderland Medical Centre Sittard, Sittard-Geleen, the Netherlands (van den Berkmortel); Department of Medical Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands (Blank); Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands (Boers-Sondereren); Isala Oncology Center, Zwolle, the Netherlands (de Groot); Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands (Hospers); Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands (Kapiteijn); Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands (May); Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, the Netherlands (de Meza, Wouters); Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands (de Meza, Wouters); Department of Internal Medicine, Medisch Spectrum Twente, Enschede, the Netherlands (Piersma); Department of Internal Medicine, Medical Centre Leeuwarden, Leeuwarden, the Netherlands (van Rijn); Department of Internal Medicine, Amphia Hospital, Breda, the Netherlands (Stevense-den Boer); Departments of Medical Oncology and Radiology and Nuclear Medicine, Erasmus Medical Centre, Rotterdam, the Netherlands (van der Veldt); Department of Internal Medicine, Maxima Medical Centre, Eindhoven, the Netherlands (Vreugdenhil); Department of Pathology, University Medical Centre Utrecht, Utrecht, the Netherlands (Blokx).

Author Contributions: Dr van Not had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: van Not, Verheijden, Haanen, de Meza, Piersma, Vreugdenhil, Blokx, Wouters, Suijkerbuijk.

Acquisition, analysis, or interpretation of data:

van Not, Verheijden, van den Eertwegh, Aarts, van den Berkmortel, Blank, Boers-Sondereren, de Groot, Hospers, Kamphuis, Kapiteijn, May, de Meza, Piersma, van Rijn, Stevense-den Boer, van der Veldt, Vreugdenhil, Blokx, Wouters, Suijkerbuijk.

Drafting of the manuscript: van Not, Verheijden, Piersma, Stevense-den Boer, Blokx.

Critical revision of the manuscript for important intellectual content: van Not, Verheijden,

van den Eertwegh, Haanen, Aarts, van den Berkmortel, Blank, Boers-Sondereren, de Groot, Hospers, Kamphuis, Kapiteijn, May, de Meza, van Rijn, Stevense-den Boer, van der Veldt, Vreugdenhil, Blokx, Wouters, Suijkerbuijk.

Statistical analysis: van Not, Verheijden, Kapiteijn, Suijkerbuijk.

Administrative, technical, or material support: van Not, van den Eertwegh, van den Berkmortel, de Groot, Hospers, Kapiteijn, Piersma, van Rijn, Stevense-den Boer, van der Veldt.

Supervision: Verheijden, de Groot, de Meza, Stevense-den Boer, Vreugdenhil, Blokx, Wouters, Suijkerbuijk.

Conflict of Interest Disclosures: Dr van den Eertwegh reported serving on the advisory boards for Bristol Myers Squibb, MSD, Amgen, Pierre Fabre, Roche, Sanofi, Ipsen, Pfizer, Merck, and Novartis; grants from Sanofi, Roche, Bristol Myers Squibb, Idera, and Teva; travel expenses from MSD Oncology, Roche, Pfizer, and Sanofi; and speaker honoraria from Bristol Myers Squibb and Novartis. Prof Haanen reported grants from Asher Bio, Amgen, Bristol Myers Squibb, MSD, BioNTech, Neogene Therapeutics, and Novartis, as well as personal fees from Aimm, Achilles Therapeutics, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, BioNTech, GSK, Immunocore, Instil Bio, Iovance Biotherapeutics, Ipsen, MSD, Merck Serono, Molecular Partners, Novartis, Neogene Therapeutics, Pfizer, Roche/Genentech, Sanofi, Scenic, Seattle Genetics, Third Rock Ventures, T-Knife, and Vaximm, all paid to institution. Dr Aarts reported consultancy honoraria from Amgen, Bristol Myers Squibb, Novartis, MSD/Merck, Merck/Pfizer, Pierre Fabre, Sanofi, Astellas, and Bayer, as well as grants from Merck/Pfizer, all paid to institution. Dr Boers-Sondereren reported

consultancy honoraria from Pierre Fabre, MSD, and Novartis. Dr Blank reported grants from Novartis, Bristol Myers Squibb, and NanoString; serving on the advisory boards for Bristol Myers Squibb, MSD, Roche, Novartis, GlaxoSmithKline, AstraZeneca, Pfizer, Lilly, GenMab, and Pierre Fabre; and ownership interest in Uniti Cars, Neon Therapeutics, and Forty Seven. Dr de Groot reported personal fees from Bristol Myers Squibb, MSD, Pierre Fabre, Servier, and Novartis. Dr Hospers reported consultancy honoraria from Amgen, Bristol Myers Squibb, Roche, MSD, Pfizer, Novartis, and Pierre Fabre, as well as grants from Bristol Myers Squibb and Seerave, paid to institution. Dr Kapiteijn reported consultancy honoraria from Bristol Myers Squibb, Novartis, Merck, and Pierre Fabre, as well as grants from Bristol Myers Squibb and Pierre Fabre. Dr Piersma reported personal fees from Novartis, Bristol Myers Squibb, and Pierre Fabre, paid to institution. Dr van Rijn reported consultancy honoraria from Pfizer and an expert meeting fee from Roche. Dr van der Veldt reported consultancy honoraria from Bristol Myers Squibb, MSD, Eisai, Roche, Merck, Sanofi, Pierre Fabre, Pfizer, Ipsen, and Novartis, paid to institution. Dr Suijkerbuijk reported grants from Bristol Myers Squibb, TigeTx, and Philips, as well as personal fees from Bristol Myers Squibb, MSD, Roche, Novartis, Pierre Fabre, and AbbVie, paid to institution. No other disclosures were reported.

Additional Information: For the Dutch Melanoma Treatment Registry (DMTR), the Dutch Institute for Clinical Auditing foundation received a start-up grant from governmental organization The Netherlands Organization for Health Research and Development (ZonMW, project number 836002002). The DMTR is structurally funded by Bristol Myers Squibb, MSD, Novartis, and Roche Pharma. Roche Pharma stopped funding in 2019, and Pierre Fabre started funding the DMTR in 2019. For this work, no funding was granted.

REFERENCES

- van Zeijl MCT, Haanen JBAG, Wouters MWJM, et al. Real-world outcomes of first-line anti-PD-1 therapy for advanced melanoma: a nationwide population-based study. *J Immunother*. 2020;43(8):256-264. doi:10.1097/JCI.0000000000000334
- Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. *N Engl J Med*. 2019;381(16):1535-1546. doi:10.1056/NEJMoa1910836
- Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and

- ipilimumab in advanced melanoma. *N Engl J Med*. 2017;377(14):1345-1356. doi:10.1056/NEJMoa1709684
4. Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. *J Clin Oncol*. 2015;33(28):3193-3198. doi:10.1200/JCO.2015.60.8448
 5. Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. *J Clin Oncol*. 2017;35(7):785-792. doi:10.1200/JCO.2015.66.1389
 6. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. *Cancer Treat Rev*. 2016;44(February):51-60. doi:10.1016/j.ctrv.2016.02.001
 7. Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? a systematic review and meta-analysis. *BMC Med*. 2020;18(1):87. doi:10.1186/s12916-020-01549-2
 8. Eggermont AMM, Kicinski M, Blank CU, et al. Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. *JAMA Oncol*. 2020;6(4):519-527. doi:10.1001/jamaoncol.2019.5570
 9. Verheijden RJ, May AM, Blank CU, et al. Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD-1-treated patients in the Dutch Melanoma Treatment Registry. *Clin Cancer Res*. 2020;26(9):2268-2274. doi:10.1158/1078-0432.CCR-19-3322
 10. Haanen JBAG, Carbonnel F, Robert C, et al; ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2017;28(suppl 4):iv119-iv142. doi:10.1093/annonc/mdx225
 11. Petrelli F, Signorelli D, Ghidini M, et al. Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. *Cancers (Basel)*. 2020;12(3):1-13. doi:10.3390/cancers12030546
 12. Wang Y, Yang M, Tao M, et al. Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment. *Int Immunopharmacol*. 2021;99(July):108031. doi:10.1016/j.intimp.2021.108031
 13. Bai X, Hu J, Betof Warner A, et al. Early use of high-dose-glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy. *Clin Cancer Res*. 2021;27(21):5993-6000. doi:10.1158/1078-0432.CCR-21-1283
 14. Chen AY, Wolchok JD, Bass AR. TNF in the era of immune checkpoint inhibitors: friend or foe? *Nat Rev Rheumatol*. 2021;17(4):213-223. doi:10.1038/s41584-021-00584-4
 15. Suijkerbuijk KPM, Verheijden RJ. TNF inhibition for immune checkpoint inhibitor-induced irAEs: the jury is still out. *Nat Rev Rheumatol*. 2021;17(8):505. doi:10.1038/s41584-021-00640-z
 16. Weber JS, Postow MA. TNF α blockade in checkpoint inhibition: the good, the bad, or the ugly? *Clin Cancer Res*. 2020;26(9):2085-2086. doi:10.1158/1078-0432.CCR-20-0387
 17. Jochems A, Schouwenburg MG, Leeneman B, et al. Dutch Melanoma Treatment Registry: quality assurance in the care of patients with metastatic melanoma in the Netherlands. *Eur J Cancer*. 2017;72:156-165. doi:10.1016/j.ejca.2016.11.021
 18. Gershenwald JE, Scolyer RA, Hess KR, et al; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA Cancer J Clin*. 2017;67(6):472-492. doi:10.3322/caac.21409
 19. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer*. 2009;45(2):228-247. doi:10.1016/j.ejca.2008.10.026
 20. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. *Control Clin Trials*. 1996;17(4):343-346. doi:10.1016/0197-2456(96)00075-X
 21. R Core Team. R: a language and environment for statistical computing. The R Foundation. Accessed September 28, 2022. <https://www.r-project.org>
 22. Therneau TM, Grambsch PM. *Modeling Survival Data: Extending the Cox Model*. Springer Nature; 2000. doi:10.1007/978-1-4757-3294-8
 23. Kassambra A, Kosinski M, Biecek P, Fabian S. Drawing survival curves using ggplot2. *survminer*. Accessed September 28, 2022. <https://rpkgs.datanovia.com/survminer/>
 24. Bass AR, Chen AY. Reply to: TNF inhibition for immune checkpoint inhibitor-induced irAEs: the jury is still out. *Nat Rev Rheumatol*. 2021;17(8):505-506. doi:10.1038/s41584-021-00641-y
 25. Wang Y, Abu-Sbeih H, Mao E, et al. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. *J Immunother Cancer*. 2018;6(1):37. doi:10.1186/s40425-018-0346-6
 26. Johnson DH, Zobniw CM, Trinh VA, et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. *J Immunother Cancer*. 2018;6(1):103. doi:10.1186/s40425-018-0412-0
 27. Lesage C, Longvert C, Prey S, et al; French Group of Onco-Dermatology. Incidence and clinical impact of anti-TNF α treatment of severe immune checkpoint inhibitor-induced colitis in advanced melanoma: the Meclolit Survey. *J Immunother*. 2019;42(5):175-179. doi:10.1097/CJI.0000000000000268
 28. Burdett N, Hsu K, Xiong L, et al. Cancer outcomes in patients requiring immunosuppression in addition to corticosteroids for immune-related adverse events after immune checkpoint inhibitor therapy. *Asia Pac J Clin Oncol*. 2020;16(2):e139-e145. doi:10.1111/ajco.13177
 29. Zou F, Faleck D, Thomas A, et al. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. *J Immunother Cancer*. 2021;9(11):e003277. doi:10.1136/jitc-2021-003277
 30. Sznol M, Ferrucci PF, Hogg D, et al. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. *J Clin Oncol*. 2017;35(34):3815-3822. doi:10.1200/JCO.2016.72.1167
 31. Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. *JAMA Oncol*. 2018;4(12):1721-1728. doi:10.1001/jamaoncol.2018.3923
 32. Schneider BJ, Naidoo J, Santomaso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline update. *J Clin Oncol*. 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440
 33. Infliximab or vedolizumab in treating immune checkpoint inhibitor-related colitis in patients with genitourinary cancer or melanoma. ClinicalTrials.gov identifier: NCT04407247. Updated June 24, 2022. Accessed October 2, 2022. <https://clinicaltrials.gov/ct2/show/NCT04407247?term=NCT04407247&draw=2&rank=1>
 34. Haslam A, Prasad V. Estimation of the percentage of us patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. *JAMA Netw Open*. 2019;2(5):e192535. doi:10.1001/jamanetworkopen.2019.2535